Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galderma Group AGXSWX:GALD -2.73%14 3-1 Month Momentum % is 9.09% as of Jul. 24, 2026. GuruFocus rates XSWX:GALD with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 1,025 Drug Manufacturers companies, Galderma Group AG ranks better than 80.88% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-24), Galderma Group AG's 3-1 Month Momentum % is 9.09%.
The industry rank for Galderma Group AG's 3-1 Month Momentum % or its related term are showing as below:
XSWX:GALD's 3-1 Month Momentum % is ranked better than 80.88% of 1025
companies
in the Drug Manufacturers industry
Industry Median: -7.9
vs XSWX:GALD: 9.09
Galderma Group AG (XSWX:GALD) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Galderma Group AG 3-1 Month Momentum % Related Terms
XSWX:GALD vs ZTS, UTHR, VTRS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's 3-1 Month Momentum % falls into.
Galderma Group AG (XSWX:GALD) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG (XSWX:GALD) has a 3-1 Month Momentum % of 9.09% as of Jul. 24, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Galderma Group AG and its competitors. According to the industry distribution chart, Galderma Group AG ranks #196 out of 1025 companies in the Drug Manufacturers industry, placing it in the top 19.1%.
Is Galderma Group AG's 3-1 Month Momentum % too high?
Galderma Group AG's current 3-1 Month Momentum % is 9.09%. Based on the distribution chart, Galderma Group AG ranks #196 out of 1025 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Galderma Group AG has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's 3-1 Month Momentum % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #196 out of 1025 companies for 3-1 Month Momentum %. This places Galderma Group AG in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Galderma Group AG and its competitors. Galderma Group AG's current 3-1 Month Momentum % is 9.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current 3-1 Month Momentum % of 9.09%. The current 3-1 Month Momentum % is 9.09%. Galderma Group AG's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current 3-1 Month Momentum % is 9.09% as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
14GF Score
Get the complete analysis for XSWX:GALD
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 
